Dr. Muhammad Asaduzzaman
Professor, Department of Clinical Pharmacy and Pharmacology,
University of Dhaka
asaduzzaman@du.ac.bd
Member Since 2020

Short Biography

Muhammad Asaduzzaman, PhD is serving as an Professor in the Department of Clinical Pharmacy and Pharmacology, University of Dhaka, Bangladesh. He has completed his graduation in Pharmacy (B.Pharm.) and Masters Degree (M.Pharm.) in Clinical Pharmacy and Pharmacology from the Faculty of Pharmacy, University of Dhaka. He was awarded Commonwealth Scholarship and completed his PhD in Clinical Medicine Research from the Department of Breast Cancer, Faculty of Medicine, Imperial College London in 2016.

In his PhD project, he worked on chemotherapy resistance mechanism in breast cancer. Using cell based models, he demonstrated a novel signaling mediated by EP300 that regulates invasiveness, CSC-like behavior and drug resistance phenotype. He is keen to do collaborative research work and has a number of local and international collaborators. He received early career research bursary awards from the British Association for Cancer Research (BACR), and is an ambassador and member of the European Association for Cancer Research (EACR). At home, he is an active member the National Young Academy of Sciences, Bangladesh (NYAB). Early in his research career, he worked on various funded projects including INSPIRE project funded by the British Council. In that project, in collaboration with Nottingham University and Dundee University, he investigated antibiotic and injection use practices in selected Upazilla Health Complex Hospitals of divisional cities of the country. He is also working as the co-principal investigator in a centennial project grant of University of Dhaka in which he already succeeded to synthesize anticancer molecules with promising activities.

Selected Publications

  1. Sufia Islam, Nazia Hoque, Nishat Nasrin, Mehnaz Hossain, Farhana Rizwan, Kushal Biswas, Muhammad Asaduzzaman, Sabera Rahman, David W. Hoskin, Saki Sultana and Christian Lehmann. Iron overload and breast cancer: Iron chelation as a potential therapeutic approach. Life, June 2022, 12:963.
  2. Md Nazmus Samdani, Niaz Morshed, Rumman Reza, Muhammad Asaduzzaman and Abul Bashar Mir Md. Khademul Islam. Targeting SARS-CoV-2 non-structural protein 13 via helicase-inhibitor-repurposing and non-structural protein 16 through pharmacophore-based screening. Mol Divers June, 2022.
  3. Tasmia Ahmed, S. M. Abdur Rahman, Muhammad Asaduzzaman, Abul Bashar Mir Md. Khademul Islam, A. K. Azad Chowdhury. Synthesis, in vitro bioassays, and computational study of heteroaryl nitazoxanide analogs. Pharmacol. Res. Perspect. June 2021. 9(3): e00800,

Zimam Mahmud, Muhammad Asaduzzaman, Uttom Kumar, Nahal Masrour, Roman Jugov, Charles Coombes, Sami Shousha, Yunhui Hu, Eric Lam, Ernesto Yague. Oncogenic EP300 can be targeted with inhibitors of aldo-keto reductases. Biochem. Pharmacol., 2019. Vol. 163: 391-403. https://doi.org/10.1016/j.bcp.2019.03.009